World's Best Scientists 2026 revealed!
Peter L. Greenberg

Peter L. Greenberg

D-Index & Metrics

Medicine

D-Index
83
Citations
37412
World Ranking
15386
National Ranking
7760

Overview

Peter L. Greenberg is affiliated with Stanford University in the United States and focuses primarily on medical research. Their work encompasses several key fields including hematology, genetics, molecular biology, oncology, and immunology. Among these, hematology and genetics constitute the majority of their published research.

The scientist's research addresses various topics within medical science, with significant emphasis on:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hemoglobinopathies and Related Disorders
  • Otitis Media and Relapsing Polychondritis
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia Research
  • Hematological disorders and diagnostics

Peter L. Greenberg's publications appear frequently in specialized journals related to hematology and oncology. Their most common publication venues include:

  • Blood
  • Leukemia
  • Blood Advances
  • Leukemia Research
  • Clinical Lymphoma Myeloma & Leukemia

Recent significant papers that illustrate the scope and focus of Greenberg's work are:

  • "Molecular International Prognostic Scoring System for Myelodysplastic Syndromes," 2022, NEJM Evidence
  • "Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes," 2020, Nature Medicine
  • "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes," 2020, New England Journal of Medicine
  • "SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS," 2020, Blood
  • "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms," 2021, Leukemia

Throughout their career, Peter L. Greenberg has frequently collaborated with other researchers in their field. Recurrent co-authors include:

  • Uwe Platzbecker
  • Pierre Fenaux
  • Michael R. Savona
  • Valeria Santini
  • Amy E. DeZern

Best Publications

  • International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

    Peter Greenberg;Christopher Cox;Michelle M. LeBeau;Pierre Fenaux

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes

    Rui Chen;George I. Mias;Jennifer Li-Pook-Than;Lihua Jiang

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

    Corey S. Cutler;Stephanie J. Lee;Peter Greenberg;H. Joachim Deeg

  • Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

    Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch

  • New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

    Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

    Eva Hellström‐Lindberg;Robert Negrin;Richard Stein;Sanford Krantz

  • Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

    Sophie Park;Sophie Grabar;Charikleia Kelaidi;Odile Beyne-Rauzy

  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

    Greenberg Pl;Attar E;Bennett Jm;Bloomfield Cd

  • Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

    Elaine M. Sloand;Colin O. Wu;Peter Greenberg;Neal Young

  • Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.

    Robert S. Negrin;Douglas H. Haeuber;Arnon Nagler;Lynne C. Olds

  • Granulopoiesis in acute myeloid leukemia and preleukemia.

    Peter L. Greenberg;William C. Nichols;Stanley L. Schrier

  • Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

    Peter L. Greenberg;Sandra J. Lee;Ranjana Advani;Martin S. Tallman

  • Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

    John Koreth;Joseph Pidala;Waleska S. Perez;H. Joachim Deeg

Frequent Co-Authors

Pierre Fenaux
Pierre Fenaux Université Paris Cité
John M. Bennett
John M. Bennett University of Rochester Medical Center
Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Guillermo Sanz
Guillermo Sanz Hospital Universitari i Politècnic La Fe
Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Peter Valent
Peter Valent Medical University of Vienna
Mario Cazzola
Mario Cazzola University of Pavia
Alan F. List
Alan F. List Precision BioSciences
Francesc Solé
Francesc Solé Autonomous University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always start with a traditional MD program. Many students begin their journey by pursuing related healthcare degrees online. Nursing remains a popular and flexible pathway, with diverse opportunities for advancement and specialization.

Those seeking to balance affordability and quality in their education can consider cheapest fnp programs online or explore affordable online nursing programs. These programs offer a cost-effective route to earning credentials while maintaining work-life flexibility.

For registered nurses looking to increase their qualifications and earning potential, the average cost of rn to bsn programs is an important consideration. Advancing further, online doctoral programs are increasingly accessible, with phd nursing education online programs preparing graduates for leadership, research, and teaching roles.

Whether you are just starting out or seeking to advance in your healthcare career, these online options provide flexible and affordable pathways to success in Medicine and related fields.

Best Scientists Citing Peter L. Greenberg

Trending Scientists